Revealing the metabolic profile of brain tumors for diagnosis purposes. by Kounelakis, M.G. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/81673
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
  
  
Abstract— The metabolic behavior of complex brain tumors, 
like Gliomas and Meningiomas, with respect to their type and 
grade was investigated in this paper. Towards this direction the 
smallest set of the most representative metabolic markers for 
each brain tumor type was identified, using ratios of peak areas 
of well established metabolites, from 1H-MRSI (Proton 
Magnetic Resonance Spectroscopy Imaging) data of 24 patients 
and 4 healthy volunteers. A feature selection method that 
embeds Fisher’s filter criterion into a wrapper selection scheme 
was applied; Support Vector Machine (SVM) and Least 
Squares-SVM (LS-SVM) classifiers were used to evaluate the 
ratio markers classification significance. The area under the 
Receiver Operating Characteristic curve (AUROC) was 
adopted to evaluate the classification significance. It is found 
that the NAA/CHO, CHO/S, MI/S ratios can be used to 
discriminate Gliomas and Meningiomas from Healthy tissue 
with AUROC greater than 0.98. Ratios CHO/S, CRE/S, MI/S, 
LAC/CRE, ALA/CRE, ALA/S and LIPS/CRE can identify type 
and grade differences in Gliomas giving AUROC greater than 
0.98 apart from the scheme of Gliomas grade II vs grade III 
where 0.84 was recorded due to high heterogeneity. Finally 
NAA/CRE, NAA/S, CHO/S, MI/S and ALA/S manage to 
discriminate Gliomas from Meningiomas providing AUROC 
exceeding 0.90.    
I. INTRODUCTION 
RAIN tumor diagnosis often requires a resection of 
brain’s tissue in order to study in depth the type and 
grade of the tumor, as to proceed with the proper 
therapy. Such an invasive technique involves the cost of 
losing vital brain functions of the patient. Therefore, reliable 
but noninvasive techniques are required to eliminate, if 
possible, this risk. 
One of the most promising technologies towards this 
direction is the 1H-MRSI (Proton Magnetic Resonance 
Spectroscopy Imaging) which provides metabolic profile of 
the tumors through the spectra acquired from small cubic 
volume of interests (VOI) called voxels, as in Fig 1. 1H-
MRSI technology has been used in brain tumors diagnosis 
over the last decade [1]. Using these spectra, the 
concentration of known metabolites can be measured and 
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then extract the necessary metabolic information of the 
tumors. Further description of these metabolites is provided 
in the next section. 
 
 
Fig. 1. The metabolite spectrum generated from a brain voxel. Y axis: peak 
heights (metabolites concentration). X axis: frequency (position) in parts per 
million. The lined area shows the area under the metabolite’s peak. 
 
The aim of this study is to employ the metabolic 
information extracted from 24 patients and 4 healthy 
volunteers (569 voxels) in order to identify the smallest set 
of the most significant metabolic markers that could be used 
to accurately describe the type and grade of the tumors, thus 
assisting the diagnosis practice. For this purpose, ratios of 
the areas under the metabolites peaks are used. Measuring 
the metabolites’ peak area ratios has the advantage of 
canceling out the effects of general reduction in measured 
metabolite concentrations, which are due to variations in 
cellular density. 
Ratios of metabolites peak areas have been already used 
in the classification of several types of tumors [2], [3]. Most 
of previous studies, however, only deal with the ratios of 
two or three known metabolites such as NAA (N-acetyl-
aspartate, CRE (Creatine) and CHO (Choline). The novelty 
here is that 31 different peak area ratios are constructed and 
tested from 12 known metabolites indicated in Fig. 1. The 
process of feature selection with the subsequent evaluation 
of the classification accuracy forms a subjective way of 
selecting the most effective subset of such ratios. 
II. MATERIALS AND METHODS 
A. Materials 
The core dataset consists of 569 pre-processed spectral 
sets containing MRS data from 24 brain tumor patients and 
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4 control persons. More specifically, there are 10 Gliomas 
patients of Grade II, 4 of Grade III, 7 of Grade IV and 3 
Meningiomas patients. Each patient passed strict quality 
control and validation procedures, including consensus 
histopathologic determination. Per tissue type voxels were 
taken from homogeneous regions. The Healthy tissue from 
patients was collected from the contralateral half of the 
brain.   
The areas under the metabolites’ peaks were obtained by 
peak integration [4]. More specifically, these areas were 
estimated by integrating the spectral intensities of each 
metabolite within a window of 0.13 ppm, Fig. 1, in the range 
0.5 to 4.0 ppm. This range is the most suitable to obtain 
secure measurements since the metabolites’ peaks can be 
easily measured. Metabolites of particular interest include 
total Creatine (CRE1 with peak at 3.95 ppm), Glutamate 
(GLU1 with peak at 3.75 ppm), Myo-inositol (MI with peak 
at 3.56 ppm), Glutamate/Glutamine (GLX with peak at 3.44 
ppm), Choline (CHO with peak at 3.20 ppm),  Creatine 
(CRE with peak at 3.02 ppm), Glutamine (GLU2 with peak 
at 2.20 ppm), N-acetyl aspartate (NAA with peak at 2.02 
ppm), Alanine (ALA with peak at 1.48 ppm), Lactate (LAC 
with peak at 1.33 ppm), Lipids1 (L1 with peak at 1.30 ppm) 
and Lipids2 (L2 with peak at 0.90 ppm). The 0.13 ppm 
window was selected as a good integration area covering the 
range of most peaks of interest, without being contaminated 
with neighboring peaks. The selected metabolites have also 
a biological relation in tumor formation [5].  
The classification schemes designed were the following: 
Healthy vs Tumors, Healthy vs Gliomas, Healthy vs 
Meningiomas, Gliomas Grade II (GR2) vs Gliomas Grade 
III (GR3), Gliomas Grade II vs Gliomas Grade IV (GR4), 
Gliomas Grade III vs Gliomas Grade IV (Glioblastomas), 
Gliomas Grade II vs Meningiomas (MNG), Gliomas Grade 
III vs Meningiomas and Gliomas Grade IV vs Meningiomas. 
 
B. Feature Selection & Classification Method 
In order to identify the most significant metabolic markers 
that could suggest an alternative, noninvasive diagnosis 
protocol, a feature selection and classification method was 
adopted, which has been previously used on genomic data 
with remarkable results [6]. A feature set of 31 ratios of 
metabolites’ peak areas was entered to the algorithm in order 
to select, through a recursive feature elimination process, the 
smallest set of the most significant ratio markers, for each 
brain tissue type. Subsequently, the discrimination power of 
these markers was evaluated through the 9 different binary 
classification schemes, using Support Vector Machines 
(SVMs) and Least Square-Support Vector Machines (LS-
SVMs) classifiers with a Radial Basis Function (RBF) 
kernel [7], [8]. Kernel-based methods can perform well in 
processing when high dimensional and heterogeneous data 
are under scrutiny. Even more, these methods are able to 
cope with possible discrepancies of feature values since they 
map them, through the kernel technique, to another space 
called feature space where linear discrimination can be 
applied.  These facts motivated the inclusion of SVM and 
LS-SVM in this study.  
Another important characteristic of this method is that the 
Fisher’s criterion in (1) is embedded in the feature selection 
process in order to rank the ratio features. This criterion is 
applied only to the Support Vectors of the two classes 
(positive and negative), since these form the most 
representative vectors for classification. Through the 
selection scheme, the least significant ratio feature, i.e. the 
ratio feature with the smallest Fisher’s value is discarded 
after each iteration and the most significant ones are kept for 
further classification purposes. This process is repeated until 
the best classification accuracy reached with the smallest 
possible number of ratio features. In this way the smallest 
set of the most significant ratio markers is selected for each 
classification scheme and presented in the next section, in 
Table I. The Fisher’s criterion has the form 
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where ( ) ( )i ix xμ μ+ −−  and ( ) ( )i ix xσ σ+ −+  are the 
mean and standard deviation values of feature ix  in the 
positive and negative classes, respectively. 
The evaluation of classifier performance was assessed 
through two different strategies, namely 10-fold Cross 
Validation (CV) and Leave-One-Patient-Out CV. 
Classification accuracy was measured in terms of AUROC 
values, along with the associated Confidence Intervals (CI) 
which indicates the expected deviation of accuracy and 
reflects the generalization ability of the classification 
scheme. 
Statistical significance of the selected ratio markers was 
also measured through Independent-Samples T test method. 
The means of the ratio markers were estimated in both 
classes and the p-values were computed. A ratio marker was 
considered significant when its p-value was less than 0.05 
and highly significant for less that 0.001.  
III. EXPERIMENTAL RESULTS 
The experimental results are presented in Tables I and II, 
regarding the selected markers and their significance, 
respectively. More specifically, the smallest sets of 
significant features achieving the best AUROC measure are 
indicated in Table I for the classification problems 
considered. Furthermore, Table II illustrates schematically 
the significance of features where a single arrow denotes a 
significant ratio marker, while double arrow corresponds to 
a highly significant ratio marker. The upwards direction of 
the arrow reflects an increase of the ratio’s mean in the 
second class while downwards implies a decrease.  
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TABLE I 
MOST SIGNIFICANT FEATURES FOR EACH BINARY CLASSIFICATION SCHEME 
LIPS = L1+L2, S = sum of the 12 metabolites peak areas, CI = Confidence Interval of the AUROC values 
 
TABLE II 
BEHAVIOR OF THE RATIO MARKERS IN EACH BINARY CLASSIFICATION SCHEME 
Binary 
schemes 
NAA / 
CHO 
NAA / 
CRE 
NAA / 
S 
CHO / 
CRE 
CHO / 
S 
CRE / 
S 
MI / 
CHO 
MI / 
CRE MI / S
LAC / 
CHO 
LAC / 
CRE 
ALA / 
CRE 
ALA / 
S 
LIPS / 
CHO 
LIPS / 
CRE 
L1 / 
CRE 
GLU1/ 
GLU2
GLX / 
CRE 
Healthy vs 
Tumors 
     
                
 
        
Healthy vs 
Gliomas 
 
    
  
      
 
  
  
            
Healthy vs 
MNG     
 
          
 
                  
GR2 vs GR3   
 
      
 
    
 
  
     
      
GR2 vs GR4         
  
    
 
      
 
          
GR3 vs GR4         
 
      
 
                  
GR2 vs MNG 
  
          
 
      
 
      
   
GR3 vs MNG 
 
  
 
  
 
  
 
  
  
    
 
          
GR4 vs MNG 
 
  
 
              
 
  
  
        
Single arrow corresponds to a significant change (p < 0.05) in the mean of the ratio marker in the second class, while double arrow reflects a highly 
significant change (p < 0.001). Upwards direction corresponds to an increase, downwards direction to a decrease in the mean.  
 
IV. DISCUSSION 
Type and grade discrimination of the tumors can be 
revealed by tracking the trends in the behavior of the ratio 
markers in each class, as presented in Table II. We can 
observe that the 9 classification schemes can be merged to 3 
major groups, which are studied next.   
A. Discrimination of Healthy tissue from Tumors 
Healthy vs Tumorous tissues discrimination can be 
achieved by examining the 3 NAA ratios, the 2 CHO ratios 
and the LIPS/CHO ratio. It can be observed that NAA/CHO,  
 
NAA/S and CHO/S are highly significant markers. This also 
reveals that high grade tumors are contained in the Tumors 
class due to the fact that NAA is highly decreased in high 
grade tumors like GR4 and that CHO and LIPS are also 
increased in Gliomas and in some cases of Meningiomas [9].  
Discrimination of Healthy vs Gliomas can be obtained by 
examining the NAA/CHO ratio, the 2 CHO ratios and the 
MI/S, LAC/CRE and ALA/CRE ratios. As already 
mentioned, NAA/CHO and CHO/S ratios are expected to be 
highly significant markers in this case. MI/S ratio is also 
highly significant due to the fact that MI is high in Low 
Binary  
schemes Most frequent features at best AUROC 
Best  
AUROC / CI 
Healthy vs 
Tumors NAA/CHO  CHO/CRE  CHO / S NAA/CRE LIPS/CHO NAA / S   0.99 / 0.004 
Healthy vs 
Gliomas NAA/CHO CHO/CRE CHO / S  LAC/CRE  ALA/ CRE MI / S   0.99 / 0.005 
Healthy vs 
MNG MI / S NAA / S       0.98 / 0.009 
GR2 vs 
GR3 LIPS/CRE CRE / S LIPS/CHO LAC/CRE ALA/CRE MI / S ALA / S NAA/CRE 0.84 / 0.028 
GR2 vs 
GR4 CRE / S CHO / S MI / S ALA / S     0.99 / 0.004 
GR3 vs 
GR4 CHO / S MI / S       0.98 / 0.013 
GR2 vs 
MNG NAA/CHO ALA/CRE GLU1/GLU2 L1/ CRE NAA/CRE MI/ CRE GLX/CRE  0.92 / 0.022 
GR3 vs 
MNG ALA / S NAA/CHO MI / S LAC/CHO MI/CHO NAA / S CHO / S  0.94 / 0.015 
GR4 vs 
MNG NAA/CHO LIPS/CHO NAA / S LAC/CRE ALA / S    0.90 / 0.018 
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Grade Gliomas like GR2 and some cases of GR3 [10] but 
low in GR4. Even more LAC is increased, CRE is decreased 
and sometimes ALA observed increased in Gliomas [9]. 
Healthy tissues can be distinguished from MNG by 
examining the NAA/S and the MI/S ratios. MI/S is highly 
significant due to the fact that MI is almost absent in 
Meningiomas but not in Healthy tissue [11]. Also NAA is 
expected to be decreased in MNG [9]. 
B. Discrimination of Gliomas 
Discrimination of Gliomas Grade II (GR2) from Gliomas 
Grade III (GR3) can be obtained by taking under 
consideration the ratios NAA/CRE, CRE/S, MI/S, 
LAC/CRE but also the 2 ALA and 2 LIPS ratios. The highly 
significant ratios of CRE/S, LAC/CRE, ALA/CRE, ALA/S 
and the LIPS/CRE reveal the effects of CRE, which is 
reduced in High Grade Gliomas like GR3, but also the 
metabolic behaviour of LIPS, LAC and sometimes ALA that 
are increased in these tumors [11]. For discriminating 
Gliomas Grade II (GR2) from the Highest Grade Gliomas 
(GR4), also called Glioblastomas, four highly significant 
ratios have to be evaluated. These are the CHO/S, CRE/S, 
MI/S and ALA/S ratios. As already mentioned, as tumor 
grade increases the CRE is decreased and the CHO is 
elevated. MI, as mentioned, is also increased in Low Grade 
Gliomas (GR2) but is low in GR4. Gliomas Grade III and 
Grade IV, usually have metabolic similarities due to the fact 
that they are often observed in necrotic areas, with increased 
lipids and lactate. This fact reflects the importance of 
CHO/S and MI/S ratios, which are able to distinguish the 
two tumor types, due to greater increase of CHO and 
decrease of MI in Gliomas Grade IV. 
C.  Discrimination of Gliomas from Meningiomas 
Gliomas and Meningiomas are originated in different 
areas of brain. ALA is increased in Meningiomas [12]. So, 
both Low Grade Gliomas (GR2), intermediate (GR3) and 
High Grade Gliomas (GR4) can be differentiated from 
Meningiomas using the ratios ALA/CRE and ALA/S. As 
Table II indicates, however, it seems that L1 [13] and GLX 
[14] play an important role in GR2 vs Meningiomas similar 
to the NAA/CRE ratio, since NAA is more reduced in 
Meningiomas than GR2 [9]. Other significant ratio marker 
that also contribute is the MI/S, since MI is almost absent in 
Meningiomas [11].  
 
It is worth emphasizing that Table I includes those 
features that provide the best AUROC measure per 
classification scheme. Thus, all other ratio-features were 
discarded by the feature selection process as not of high 
importance for the discrimination of tumors. In other words, 
discarded features had no additional value in accuracy. This 
study, in contrast to others [2], [3] involving ratio-type 
features to discriminate brain tumors, aims at revealing the 
smallest possible set of ratio features that can successfully 
classify a new subject to one of the classes considered. For 
this purpose, the discriminative potential of new ratio 
features, which have not been considered before, was 
extensively studied. 
V. CONCLUSIONS 
It becomes widely accepted that metabolomics is a highly 
promising field that will definitely accelerate the discovery 
of individualised therapies for brain cancer. Along these 
directions, the processing of the metabolite spectrum (area 
under the peaks and the ratios of metabolite areas under the 
peaks) has derived features that enable the effective 
classification of several types of brain tumors. Advanced 
feature selection methods further enable the specification of 
ratio combinations that allow for high discriminative power.   
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